Drugs / Xeligekimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07339566 | Jan 2026 → Jun 2027 expected | spondyloarthropathy | Lingli Dong | Not yet recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05881785 | Jun 2022 → Dec 2023 | ankylosing spondylitis | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT07503652 | Mar 2026 → Dec 2027 expected | palmoplantar pustulosis | First Hospital of China Medical University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Results 四十年薪火相传，国产IL-17A破局——CRA年会圆满落幕 genrixbio.com ↗
治疗至32周，200mg组ASAS20应答率达82.5%。 |
| 2025-12-07 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Regulatory 智翔金泰赛立奇单抗成功纳入2025年国家医保目录，惠及更多中国患者 genrixbio.com ↗
重庆智翔金泰生物制药股份有限公司（以下简称“智翔金泰”）宣布，公司自主研发的1类生物创新药——赛立奇单抗注射液（金立希®）成功纳入国家医保目录。 |
| 2025-06-13 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Results 从本土创新到国际舞台：赛立奇单抗Ⅲ期数据奏响2025年EULAR“中国之声” genrixbio.com ↗
在本次大会上，我国自主研发的IL-17A抑制剂赛立奇单抗亮相国际大会，来自中国医学科学院北京协和医院风湿免疫科的王迁教授在当地时间6月11日以口头报告形式重磅公布了赛立奇单抗治疗强直性脊柱炎的Ⅲ期临床研究结果。 |
| 2024-08-27 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Regulatory 国产首个！智翔金泰自主研发的全人源抗IL-17A单抗——赛立奇单抗获批上市 genrixbio.com ↗
8月27日，智翔金泰（股票代码：688443）宣布，公司自主研发的1类新药赛立奇单抗注射液（商品名：金立希®）正式获得国家药品监督管理局（NMPA）核准签发的《药品注册证书》，正式获批上市，用于中、重度斑块状银屑病的治疗。 |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 四十年薪火相传，国产IL-17A破局——CRA年会圆满落幕 genrixbio.com ↗ |
| 2025-12-07 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 智翔金泰赛立奇单抗成功纳入2025年国家医保目录，惠及更多中国患者 genrixbio.com ↗ |
| 2025-06-13 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 从本土创新到国际舞台：赛立奇单抗Ⅲ期数据奏响2025年EULAR“中国之声” genrixbio.com ↗ |
| 2024-08-27 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 国产首个！智翔金泰自主研发的全人源抗IL-17A单抗——赛立奇单抗获批上市 genrixbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xeligekimab | “Xeligekimab is a novel immunoglobulin G4 (IgG4) monoclonal antibody targeting interleukin-17A (IL-17A).” PMID 41247398 ↗ Nov 2025 |
| Action | Inhibit | “Xeligekimab, an Interleukin-17A Antagonist” PMID 41247398 ↗ Nov 2025 |
| Modality | Monoclonal antibody | “Xeligekimab is a novel immunoglobulin G4 (IgG4) monoclonal antibody” PMID 41247398 ↗ Nov 2025 |
| Route | Subcutaneous | “subcutaneous injection of Xeligekimab 100mg each time” NCT07339566 ↗ |